
IKZF1 Deletions at Diagnose and Relapse of Childhood B-ALL
Erbilgin et al. (2026) used Genomize-SEQ to confirm IKZF1 deletions were nearly twice as common in relapsed pediatric B-ALL patients as at diagnosis, suggesting these deletions accumulate during disease progression rather than predicting relapse from the outset.